Dutasteride and Androgen-Ablation Therapy in Treating Patients With Localized Prostate Cancer Who Have Undergone Radiation Therapy and/or Surgery

Condition(s) targeted: Prostate Cancer

Intervention: dutasteride (Drug); placebo (Other)

Phase: Phase 2

Status: Recruiting

Sponsored by: Fred Hutchinson Cancer Research Center

Official(s) and/or principal investigator(s):
Celestia S. Higano, MD, Principal Investigator, Affiliation: Seattle Cancer Care Alliance

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using dutasteride and androgen ablation therapy may fight prostate cancer by blocking the use of androgens by the tumor cells.

PURPOSE: This randomized phase II trial is studying how well giving dutasteride together with androgen ablation therapy works in treating patients with localized prostate cancer who have undergone radiation therapy and/or surgery.

Official title: Multicentre, Double-Blind Study Comparing 0.5mg Dutasteride vs. Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer

Study design: Treatment, Randomized, Double-Blind, Placebo Control

Primary outcome: Time to PSA > 5.0 ng/mL during the off-treatment interval during intermittent androgen-ablation therapy

Secondary outcome:

Time to androgen-independent prostate cancer, as defined by a rising PSA with testosterone < 50 ng/mL

Adverse events as assessed by NCI CTCAE v3.0

Clinical laboratory evaluations (i.e., hematology, biochemistry, and total PSA)

Levels of serum testosterone and dihydrotestosterone (DHT)

Quality of life as measured by the FACT-P, IPSS, and the PAS SFI at baseline and at 9 and 24 months

PSA nadir at the end of 9 months of androgen-ablation therapy

Serum testosterone and DHT levels achieved during intermittent androgen-ablation therapy

Detailed description: OBJECTIVES:

Primary

- To assess the effect of dutasteride on the length of the off-treatment interval in

patients receiving intermittent androgen-ablation therapy for localized prostate cancer.

Secondary

- To assess the effect of dutasteride on the PSA nadir after 9 months of

androgen-deprivation therapy.

- To assess the effect of dutasteride on serum testosterone and dihydrotestosterone

levels.

- To assess the effect of dutasteride on the time to onset of androgen-independent

prostate cancer (i. e., rising PSA with testosterone < 50 ng/mL).

- To assess the safety and tolerability of dutasteride when administered in combination

with intermittent androgen-ablation therapy.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms. All patients receive intermittent androgen-ablation therapy (IAAT) comprising oral bicalutamide once daily, beginning concurrently with study medication, for 9 months and a depot injection of luteinizing hormone-releasing hormone analog once every 3 months for 9 months beginning at 3 months after initiation of study medication. An off-treatment interval (i. e., off IAAT) follows after completion of 9 months of IAAT.

- Arm I: Patients receive oral dutasteride once daily for up to 9 months* in the absence

of disease progression or unacceptable toxicity.

- Arm II: Patients receive oral placebo once daily for up to 9 months* in the absence of

disease progression or unacceptable toxicity.

NOTE: *Patients with a serum PSA value < 1. 0 ng/mL at the end of 9 months continue dutasteride once daily for up to 21 months until serum PSA increases to ≥ 5. 0 ng/mL.

Patients undergo blood sample collection at baseline and periodically for pharmacodynamic analysis. Samples are analyzed for circulating levels of serum testosterone and dihydrotestosterone.

Quality of life is assessed at baseline and 9 or 24 months.

Minimum age: 45 Years. Maximum age: 80 Years. Gender(s): Male.

Criteria:

DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the prostate

- Localized disease

- Known Gleason grade

- Received prior external-beam radiotherapy, brachytherapy, or radical prostatectomy

- Candidate for intermittent androgen-ablation therapy

- Minimum of 3 PSA values above the nadir PSA measured ≥ 1 month apart after treatment

AND meets 1 of the following criteria:

- PSA level ≥ 2. 0 ng/mL and < 100 ng/mL in patients who underwent prior radical

prostatectomy with or without radiotherapy

- PSA level ≥ 3. 0 ng/mL and < 100 ng/mL in patients who underwent external beam

radiotherapy (at any time) or brachytherapy > 3 years ago

- PSA level ≥ 6. 0 ng/mL and < 100 ng/mL in patients who underwent brachytherapy

within the past 3 years

- Serum testosterone ≥ 250 ng/dL

- Negative bone scan within the past 12 months

- No distant metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

- ECOG performance status 0-1

- Able to read and write, understand instructions related to study procedures, and give

written informed consent

- Able to swallow and retain oral medication

- Able and willing to participate in the full study

Exclusion criteria:

- Unstable serious concurrent medical conditions including, but not limited to, any of

the following:

- Myocardial infarction

- Unstable angina

- Cardiac arrhythmias

- Clinically evident congestive heart failure or cerebrovascular accident within

the past 6 months

- Uncontrolled diabetes

- Peptic ulcer disease

- Alkaline phosphatase, ALT, or AST > 2 times upper limit of normal (ULN)

- Bilirubin > 1. 5 times ULN

- Serum creatinine > 1. 5 times ULN

- Other malignancy within the past 5 years except curatively treated basal or squamous

cell skin cancer or Ta bladder cancer with negative surveillance cystoscopy within the past 2 years

- History or current evidence of drug or alcohol abuse within the past year

- History of any illness that, in the opinion of the investigator, might confound the

results of the study or pose additional risk to the patient

- Known hypersensitivity to any 5α-reductase inhibitor or to any drug chemically

related to dutasteride

- Known hypersensitivity to bicalutamide or to any drug chemically related to

bicalutamide

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior treatment for prostate cancer with any of the following:

- Chemotherapy

- Hormonal therapy (e. g., megestrol, medroxyprogesterone, cyproterone, or

diethylstilbestrol) within the past year

- May have received ≤ 12 months of neoadjuvant or adjuvant

androgen-deprivation therapy provided the therapy was discontinued > 1 year ago

- Glucocorticoids (except inhaled or topical drugs) within the past 3 months

- Ketoconazole

- Luteinizing hormone releasing-hormone analogs (e. g., leuprolide or goserelin) or

nonsteroidal antiandrogens (e. g., bicalutamide or flutamide) within the past year

- More than 30 days since prior and no other concurrent investigational agents

- More than 1 year since prior dutasteride

- More than 1 year since prior and no concurrent use of the following medications:

- Finasteride

- Other investigational 5α-reductase inhibitors

- Anabolic steroids

- Medications with antiandrogenic properties

- Over-the-counter or herbal preparations such as cimetidine, saw palmetto,

selenium (> 75 mcg), or vitamin E (> 100 IU)

- No coronary bypass surgery within the past 6 months

Cascade Cancer Center at Evergreen Hospital Medical Center, Kirkland, Washington 98034-3013, United States; Recruiting
Brenda Havens, Phone: 425-899-3181, Email: bhavens@cascadecancercenter.com

Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington 98101, United States; Recruiting
Jacqueline Vuky, MD, Phone: 206-223-6193, Email: jacqueline.vuky@vmmc.org

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington 98195-6043, United States; Recruiting
Alma MacAraeg, Phone: 206-288-1349, Email: almam@u.washington.edu

MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington 98405, United States; Recruiting
Richard Shine, PharmD, Phone: 253-403-7250, Email: Richard.Shine@multicare.org

Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington 98273, United States; Recruiting
Robert J. Raish, MD, Phone: 360-428-2146

University Cancer Center at University of Washington Medical Center, Seattle, Washington 98195-6043, United States; Recruiting
Alma MacAraeg, Phone: 206-288-1349, Email: almam@u.washington.edu

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: December 2006
Last updated: August 25, 2009